VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | Complement inhibitor therapy for myasthenia gravis: current and future outlooks

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the current and future role of complement inhibitor therapy for patients with myasthenia gravis. Currently, complement inhibitor therapy is mainly used in patients who have failed multiple immunotherapeutics, although their indication is for generalized myasthenia gravis without restrictions. In the future, complement inhibitors should be used in earlier lines of treatment and might be used in combination with other agents. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


Research support paid to institution: Alexion Pharmaceuticals, Argenx BVBA, Cartesian Therapeutics, The Centers for Disease Control and Prevention, Millennium/Takeda Pharmaceuticals, National Institutes of Health, PCORI, Ra Pharmaceuticals (now UCB)
Honoraria: Alexion Pharmaceuticals, Argenx BVBA, Ra Pharmaceuticals (now UCB), Immunovant, Regeneron Pharmaceuticals, Sanofi US, Toleranzia AB, Viela Bio Inc (now Horizon Therapeutics)
Stock dividends: Johnson & Johnson, Pfizer, General Electric, GlaxoSmithKline